[Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
Hirata
Takuya
T
takuya.hirata@jp.astellas.com
Funatsu
Toshiyuki
T
Keto
Yoshihiro
Y
Akuzawa
Shinobu
S
Akiho
Hiraku
H
Nishida
Akito
A
Sasamata
Masao
M
Miyata
Keiji
K
D000818:Animals; D001562:Benzimidazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D013315:Stress, Psychological / Q000150:complications
D001562:Benzimidazoles; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists; C071315:ramosetron